PureTech Receives FDA Fast Track Designation for LYT-200 in Head and Neck Cancers

Apr 11

Written By Allison Talbot

Allison Talbot

PureTech Receives FDA Fast Track Designation for LYT-200 in Acute Myeloid Leukemia (AML)

PureTech Receives Orphan Drug Designation for LYT-200 in Acute Myeloid Leukemia